BioTime, Inc. (NYSE MKT: BTX) announced that the company has amended its license from the University of Utah to expand the field of use for which BioTime is licensed to produce and market products ...

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along ...

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with ...

Discovery from The Wistar Institute covers the SP100 gene. BioTime obtained an exclusive license from The Wistar Institute for technology related to a gene called SP100 implicated in cancer and stem ...

ALAMEDA, Calif.--BioTime, Inc. (NYSE MKT: BTX), today announced that it has initiated the development of two new products based on its HyStem® hydrogel technology platform. The first of these new ...

MADISON - BioTime, Inc. (OTCBB: BTIM) has signed a licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for 173 patents and patent applications relating to human embryonic stem ...

Stem cell technology developer Cell Targeting has sold its assets to BioTime (AMEX:BTX) in a deal worth about $2.3 million. BioTime will pay $250,000 in cash as well as 262,000 shares of BioTime’s ...

Exclusive, worldwide rights cover age- and diabetes-related diseases and cancer as well as use in research products. BioTime entered into an exclusive license agreement with Cornell University for the ...

“Our HyStem® technology has potential utility in a wide array of human therapeutic products,” said Michael West, Ph.D., BioTime’s CEO. “Following up on the Jade agreement, we intend to seek additional ...

BioTime Announces Additional Products in Development Based on HyStem ® Technology ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX), today announced that it has initiated the ...